{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:45:41Z","timestamp":1791870341332,"version":"4.3.4"},"reference-count":106,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Triple\u2010negative breast cancers (TNBCs) are associated with poor prognosis and chemoresistance. Recent reports indicate that extracellular matrix (ECM) molecules, such as integrins, could influence TNBC development. Integrins are adhesion macromolecules that modulate ECM characteristics such as stiffening of ECM and being associated with hypoxia. Therefore, dysregulation in integrins could compromise the efficient delivery of cancer treatments. Some peptides and aptamers can directly target integrins, and they are now being studied; however, most monoclonal antibodies and PARP inhibitors that are used for TNBC do not directly target integrins. Integrins and the ECM can change the way these treatments work. Currently, the efficacy of these candidates is still being evaluated, and the majority of studies are in the early phase of development. The present article reviews the role of integrins in cancer development and captures the state\u2010of\u2010the\u2010art evidence on the therapeutic targeting of integrins in breast cancer. Also, solutions to overcome challenges in the field are suggested.<\/jats:p>","DOI":"10.1002\/cam4.72247","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:03:27Z","timestamp":1791867807000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies,\n                    <scp>PARP<\/scp>\n                    Inhibitors, Synthetic Peptides, and Aptamers"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5871-0406","authenticated-orcid":false,"given":"Mobina","family":"Darabi","sequence":"first","affiliation":[{"name":"Cancer Immunology Project (CIP) Universal Scientific Education and Research Network (USERN)  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-0895","authenticated-orcid":false,"given":"Zeynab","family":"Zahedi","sequence":"additional","affiliation":[{"name":"Cancer Immunology Project (CIP) Universal Scientific Education and Research Network (USERN)  Tehran Iran"},{"name":"USERN SEMUMS Office Universal Scientific Education and Research Network (USERN)  Semnan Iran"},{"name":"Student Research Committee Semnan University of Medical Sciences  Semnan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5220-5946","authenticated-orcid":false,"given":"Kosar","family":"Zolfaghari","sequence":"additional","affiliation":[{"name":"Cancer Immunology Project (CIP) Universal Scientific Education and Research Network (USERN)  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Kordi","sequence":"additional","affiliation":[{"name":"Cancer Immunology Project (CIP) Universal Scientific Education and Research Network (USERN)  Tehran Iran"},{"name":"Faculty of Veterinary Medicine University of Tehran  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4159-7299","authenticated-orcid":false,"given":"Kiarash","family":"Saleki","sequence":"additional","affiliation":[{"name":"Research Center for Immunodeficiencies Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Research Center for Immunodeficiencies Tehran University of Medical Sciences  Tehran Iran"},{"name":"Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN)  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1827","authenticated-orcid":false,"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Research Center for Immunodeficiencies Tehran University of Medical Sciences  Tehran Iran"},{"name":"Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) Universal Scientific Education and Research Network (USERN)  Tehran Iran"},{"name":"Department of Immunology Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"6","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: Bidirectional, Allosteric Signaling Machines","volume":"110","author":"Hynes R. O.","year":"2002","journal-title":"Cell"},{"issue":"6","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41388-020-01588-2","article-title":"Understanding the Role of Integrins in Breast Cancer Invasion, Metastasis, Angiogenesis, and Drug Resistance","volume":"40","author":"Yousefi H.","year":"2021","journal-title":"Oncogene"},{"issue":"2","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/0008-5472.CAN-06-2768","article-title":"Increased \u03b21 Integrin Is Associated With Decreased Survival in Invasive Breast Cancer","volume":"67","author":"Yao E. S.","year":"2007","journal-title":"Cancer Research"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and Other Recognition Sequences for Integrins","volume":"12","author":"Ruoslahti E.","year":"1996","journal-title":"Annual Review of Cell and Developmental Biology"},{"issue":"1","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-009-0834-6","article-title":"Integrins","volume":"339","author":"Barczyk M.","year":"2010","journal-title":"Cell and Tissue Research"},{"issue":"1","key":"e_1_2_13_7_1","first-page":"17","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel R. L.","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40364-021-00310-y","article-title":"Epidemiological Trends of Women's Cancers From 1990 to 2019 at the Global, Regional, and National Levels: A Population\u2010Based Study","volume":"9","author":"Yi M.","year":"2021","journal-title":"Biomarker Research"},{"issue":"3","key":"e_1_2_13_9_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung H.","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"15","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple\u2010Negative Breast Cancer: Clinical Features and Patterns of Recurrence","volume":"13","author":"Dent R.","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"20","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple\u2010Negative Breast Cancer","volume":"363","author":"Foulkes W. D.","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176914","article-title":"Targeting Overexpressed Surface Proteins: A New Strategy to Manage the Recalcitrant Triple\u2010Negative Breast Cancer","volume":"981","author":"Raj A.","year":"2024","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17425247.2021.1874916","article-title":"Factors Affecting the Dynamics and Heterogeneity of the EPR Effect: Pathophysiological and Pathoanatomic Features, Drug Formulations and Physicochemical Factors","volume":"19","author":"Islam R.","year":"2022","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"1","key":"e_1_2_13_14_1","first-page":"79","article-title":"The Relationship Between Bone Metastasis From Human Breast Cancer and Integrin \u03b1v\u03b23 Expression","volume":"25","author":"Takayama S.","year":"2005","journal-title":"Anticancer Research"},{"issue":"2","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020139","article-title":"Therapeutic Potential of a Novel \u03b1(v)\u03b23 Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub\u2010Type","volume":"11","author":"Hill B. S.","year":"2019","journal-title":"Cancers"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/DDDT.S52216","article-title":"Advances in the Proteomic Discovery of Novel Therapeutic Targets in Cancer","volume":"7","author":"Guo S.","year":"2013","journal-title":"Drug Design, Development and Therapy"},{"issue":"4","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10555-016-9650-0","article-title":"From Transformation to Metastasis: Deconstructing the Extracellular Matrix in Breast Cancer","volume":"35","author":"Kaushik S.","year":"2016","journal-title":"Cancer Metastasis Reviews"},{"issue":"6","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1541-7786.MCR-16-0338","article-title":"Hypoxia Selectively Enhances Integrin \u03b15\u03b21 Receptor Expression in Breast Cancer to Promote Metastasis","volume":"15","author":"Ju J. A.","year":"2017","journal-title":"Molecular Cancer Research"},{"issue":"3","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1242\/jcs.071985","article-title":"Integrin \u03b15\u03b21 Facilitates Cancer Cell Invasion Through Enhanced Contractile Forces","volume":"124","author":"Mierke C. T.","year":"2011","journal-title":"Journal of Cell Science"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88483.3","article-title":"Integrin \u03b24 Promotes DNA Damage\u2010Related Drug Resistance in Triple\u2010Negative Breast Cancer via TNFAIP2\/IQGAP1\/RAC1","volume":"12","author":"Fang H.","year":"2023","journal-title":"eLife"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101321","article-title":"Disruption of NANOG\u2010Driven Epithelial\u2010Mesenchymal Transition (EMT) and Self\u2010Renewal Restores Drug Sensitivity in Colorectal Cancer","volume":"84","author":"Saleki K.","year":"2026","journal-title":"Drug Resistance Updates"},{"issue":"1","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","DOI":"10.1007\/s12672-025-03234-3","article-title":"Interplay Between Innate\u2010Like T\u2010Cells and microRNAs in Cancer Immunity","volume":"16","author":"Yousefi M. J.","year":"2025","journal-title":"Discover Oncology"},{"issue":"4","key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1515\/revneuro-2024-0097","article-title":"Nanocarriers in Glioblastoma Treatment: A Neuroimmunological Perspective","volume":"36","author":"Firuzpour F.","year":"2025","journal-title":"Reviews in the Neurosciences"},{"issue":"11","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/1744666X.2023.2248390","article-title":"Neurological Adverse Effects of Chimeric Antigen Receptor T\u2010Cell Therapy","volume":"19","author":"Saleki K.","year":"2023","journal-title":"Expert Review of Clinical Immunology"},{"issue":"1","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","DOI":"10.5812\/ipmn-131144","article-title":"Utilizing Immunoinformatics to Target Brain Tumors; an Aid to Current Neurosurgical Practice","volume":"2","author":"Saleki K.","year":"2022","journal-title":"Interventional Pain Medicine and Neuromodulation"},{"issue":"3","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1515\/revneuro-2024-0095","article-title":"Implications of Glioblastoma\u2010Derived Exosomes in Modifying the Immune System: State\u2010of\u2010the\u2010Art and Challenges","volume":"36","author":"Afshar Y.","year":"2025","journal-title":"Reviews in the Neurosciences"},{"issue":"1","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010246","article-title":"Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer","volume":"15","author":"Pradhan R.","year":"2023","journal-title":"Pharmaceutics"},{"issue":"21","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110744","article-title":"Computer\u2010Aided Drug Design Across Breast Cancer Subtypes: Methods, Applications and Translational Outlook","volume":"26","author":"Tian W.","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13058-024-01942-2","article-title":"Cilengitide Sensitivity Is Predicted by Overall Integrin Expression in Breast Cancer","volume":"26","author":"Girnius N.","year":"2024","journal-title":"Breast Cancer Research"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ccell.2020.12.001","article-title":"Integrin \u03b1v\u03b26\u2010TGF\u03b2\u2010SOX4 Pathway Drives Immune Evasion in Triple\u2010Negative Breast Cancer","volume":"39","author":"Bagati A.","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41388-020-01603-6","article-title":"Integrin alpha5 in Human Breast Cancer Is a Mediator of Bone Metastasis and a Therapeutic Target for the Treatment of Osteolytic Lesions","volume":"40","author":"Pantano F.","year":"2021","journal-title":"Oncogene"},{"issue":"6","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061570","article-title":"Aptamer Targets Triple\u2010Negative Breast Cancer Through Specific Binding to Surface CD49c","volume":"14","author":"Wan Q.","year":"2022","journal-title":"Cancers"},{"issue":"24","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"2327\u20102341","DOI":"10.1038\/s41388-026-03780-2","article-title":"Crosstalk Between Integrin Signaling and NAD+ Biosynthetic Pathways Promotes Glycolysis, Proliferation, Survival, and Tumor Growth in Triple\u2010Negative Breast Cancer","volume":"45","author":"Spellecy O.","year":"2026","journal-title":"Oncogene"},{"issue":"2","key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.yexcr.2019.03.011","article-title":"Integrin Intracellular Machinery in Action","volume":"378","author":"Green H. J.","year":"2019","journal-title":"Experimental Cell Research"},{"issue":"1","key":"e_1_2_13_35_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41556-018-0234-9","article-title":"Integrin Activation by Talin, Kindlin and Mechanical Forces","volume":"21","author":"Sun Z.","year":"2019","journal-title":"Nature Cell Biology"},{"issue":"2","key":"e_1_2_13_36_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41580-022-00531-5","article-title":"Organization, Dynamics and Mechanoregulation of Integrin\u2010Mediated Cell\u2010ECM Adhesions","volume":"24","author":"Kanchanawong P.","year":"2023","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"312","key":"e_1_2_13_37_1","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004751","article-title":"\u03b21 Integrin Inhibition Elicits a Prometastatic Switch Through the TGF\u03b2\u2013miR\u2010200\u2013ZEB Network in E\u2010Cadherin\u2014Positive Triple\u2010Negative Breast Cancer","volume":"7","author":"Truong H. H.","year":"2014","journal-title":"Science Signaling"},{"issue":"9","key":"e_1_2_13_38_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091432","article-title":"\u03b21 Integrin as a Prognostic and Predictive Marker in Triple\u2010Negative Breast Cancer","volume":"17","author":"Yin H. L.","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"issue":"25","key":"e_1_2_13_39_1","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/onc.2012.320","article-title":"Integrin \u03b25 Contributes to the Tumorigenic Potential of Breast Cancer Cells Through the Src\u2010FAK and MEK\u2010ERK Signaling Pathways","volume":"32","author":"Bianchi\u2010Smiraglia A.","year":"2013","journal-title":"Oncogene"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3691"},{"issue":"5","key":"e_1_2_13_41_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0167-5699(96)30013-3","article-title":"Integrins as Promiscuous Signal Transduction Devices","volume":"17","author":"Petty H. R.","year":"1996","journal-title":"Immunology Today"},{"issue":"1","key":"e_1_2_13_42_1","doi-asserted-by":"crossref","DOI":"10.1038\/srep23258","article-title":"Substrate Engagement of Integrins \u03b15\u03b21 and \u03b1v\u03b23 Is Necessary, but Not Sufficient, for High Directional Persistence in Migration on Fibronectin","volume":"6","author":"Missirlis D.","year":"2016","journal-title":"Scientific Reports"},{"issue":"4","key":"e_1_2_13_43_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176226","article-title":"Inhibition of \u03b1v\u03b23 Integrin Induces Loss of Cell Directionality of Oral Squamous Carcinoma Cells (OSCC)","volume":"12","author":"Montenegro C. F.","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"e_1_2_13_44_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41580-019-0134-2","article-title":"Integrins as Biomechanical Sensors of the Microenvironment","volume":"20","author":"Kechagia J. Z.","year":"2019","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"e_1_2_13_45_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149890","article-title":"\u03b2\u2010Catenin\/TCF4\/NANOG Axis Controls miR\u2010302 Transcription in Colorectal Cancer Cells","volume":"977","author":"Saleki K.","year":"2025","journal-title":"Gene"},{"issue":"4","key":"e_1_2_13_46_1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.70073","article-title":"Testican\u20101\u2010MMP Axis in Tumour Extracellular Matrix (ECM) Remodelling: Interaction Dynamics Analysis and an in Silico Perspective","volume":"269","author":"Youssefi S.","year":"2026","journal-title":"Journal of Pathology"},{"key":"e_1_2_13_47_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1431418","article-title":"Targeted Therapy Approaches for Epithelial\u2010Mesenchymal Transition in Triple Negative Breast Cancer","volume":"14","author":"Haque M.","year":"2024","journal-title":"Frontiers in Oncology"},{"issue":"9","key":"e_1_2_13_48_1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.cellsig.2014.03.020","article-title":"Pyruvate Kinase M2 Facilitates Colon Cancer Cell Migration via the Modulation of STAT3 Signalling","volume":"26","author":"Yang P.","year":"2014","journal-title":"Cellular Signalling"},{"issue":"7","key":"e_1_2_13_49_1","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/hmg\/ddu612","article-title":"OXPHOS Dysfunction Regulates Integrin\u2010\u03b21 Modifications and Enhances Cell Motility and Migration","volume":"24","author":"Nunes J. B.","year":"2015","journal-title":"Human Molecular Genetics"},{"issue":"6","key":"e_1_2_13_50_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.7150\/thno.14988","article-title":"Current Approaches of Photothermal Therapy in Treating Cancer Metastasis With Nanotherapeutics","volume":"6","author":"Zou L.","year":"2016","journal-title":"Theranostics"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.08.030"},{"key":"e_1_2_13_51_2","unstructured":"https:\/\/pubmed.ncbi.nlm.nih.gov\/31454671."},{"issue":"7","key":"e_1_2_13_52_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073143","article-title":"Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications","volume":"26","author":"Kariya Y.","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"e_1_2_13_53_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2174\/1875533XMTAzfNzkzy","article-title":"Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment","volume":"28","author":"Silvestre A. L. P.","year":"2021","journal-title":"Current Medicinal Chemistry"},{"issue":"3","key":"e_1_2_13_54_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.surg.2019.09.018","article-title":"Current Status and Limitations of Immunotherapy for Breast Cancer","volume":"167","author":"Tokumaru Y.","year":"2020","journal-title":"Surgery"},{"issue":"2","key":"e_1_2_13_55_1","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020287","article-title":"Bio\u2010Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment","volume":"13","author":"Keihan Shokooh M.","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"e_1_2_13_56_1","first-page":"1671","article-title":"Shedding Light on Triple\u2010Negative Breast Cancer With Trop2\u2010Targeted Antibody\u2010Drug Conjugates","volume":"12","author":"Jabbarzadeh Kaboli P.","year":"2022","journal-title":"American Journal of Cancer Research"},{"issue":"4","key":"e_1_2_13_57_1","doi-asserted-by":"crossref","first-page":"PD3\u201014","DOI":"10.1158\/1538-7445.SABCS17-PD3-14","article-title":"Abstract PD3\u201014: Phase 1 Study of the Antibody\u2010Drug Conjugate SGN\u2010LIV1A in Patients With Heavily Pretreated Triple\u2010Negative Metastatic Breast Cancer","volume":"78","author":"Modi S.","year":"2018","journal-title":"Cancer Research"},{"issue":"13","key":"e_1_2_13_58_1","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1158\/1078-0432.CCR-16-2401","article-title":"Synthetic Lethality Exploitation by an Anti\u2010Trop\u20102\u2010SN\u201038 Antibody\u2010Drug Conjugate, IMMU\u2010132, Plus PARP Inhibitors in BRCA1\/2\u2010Wild\u2010Type Triple\u2010Negative Breast Cancer","volume":"23","author":"Cardillo T. M.","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_13_59_1","doi-asserted-by":"crossref","DOI":"10.12703\/r\/10-45","article-title":"The Roles of Integrins in Cancer","volume":"10","author":"Valdembri D.","year":"2021","journal-title":"Faculty Review"},{"key":"e_1_2_13_60_1","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz100.047","article-title":"196TiPSGNLVA\u2010002: Single Arm, Open Label, Phase Ib\/II Study of Ladiratuzumab Vedotin (LV) in Combination With Pembrolizumab for First\u2010Line Treatment of Patients With Unresectable Locally\u2010Advanced or Metastatic Triple\u2010Negative Breast Cancer","volume":"30","author":"Boni V.","year":"2019","journal-title":"Annals of Oncology"},{"issue":"7","key":"e_1_2_13_61_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14712598.2021.1840547","article-title":"Antibody\u2010Drug Conjugates in Metastatic Triple Negative Breast Cancer: A Spotlight on Sacituzumab Govitecan, Ladiratuzumab Vedotin, and Trastuzumab Deruxtecan","volume":"21","author":"McGuinness J. E.","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"9","key":"e_1_2_13_62_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102322","article-title":"Modulation of Fibronectin Extracellular Matrix Enhances Anti\u2010Tumor Efficacy of Immune Checkpoint Blockade","volume":"6","author":"Khan K. A.","year":"2025","journal-title":"Cell Reports Medicine"},{"issue":"5","key":"e_1_2_13_63_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab Deruxtecan: First Approval","volume":"80","author":"Keam S. J.","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"e_1_2_13_64_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2\u2010Low Advanced Breast Cancer","volume":"387","author":"Modi S.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"e_1_2_13_65_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1\/2 Open\u2010Label Study","volume":"3","author":"Powles T.","year":"2017","journal-title":"JAMA Oncology"},{"issue":"9","key":"e_1_2_13_66_1","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.apsb.2021.01.004","article-title":"Integrins as Attractive Targets for Cancer Therapeutics","volume":"11","author":"Li M.","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"5","key":"e_1_2_13_67_1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2174\/0929866511320050012","article-title":"Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma","volume":"20","author":"Li Y.","year":"2013","journal-title":"Protein and Peptide Letters"},{"issue":"20","key":"e_1_2_13_68_1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab After Chemoradiotherapy in Stage III Non\u2010Small\u2010Cell Lung Cancer","volume":"377","author":"Antonia S. J.","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"e_1_2_13_69_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41591-020-01189-2","article-title":"Durvalumab Compared to Maintenance Chemotherapy in Metastatic Breast Cancer: The Randomized Phase II SAFIR02\u2010Breast Immuno Trial","volume":"27","author":"Bachelot T.","year":"2021","journal-title":"Nature Medicine"},{"issue":"11","key":"e_1_2_13_70_1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant Durvalumab Improves Survival in Early Triple\u2010Negative Breast Cancer Independent of Pathological Complete Response","volume":"33","author":"Loibl S.","year":"2022","journal-title":"Annals of Oncology"},{"issue":"17","key":"e_1_2_13_71_1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO-25-02311","article-title":"Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple\u2010Negative Breast Cancer: Long\u2010Term Analysis From the GeparNuevo Trial","volume":"44","author":"Loibl S.","year":"2026","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_13_72_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.802579","article-title":"Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy","volume":"12","author":"Magbanua M. J. M.","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"e_1_2_13_73_1","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.21037\/tcr-19-3020","article-title":"The Efficacy and Safety of PD\u20101\/PD\u2010L1 Inhibitors in Breast Cancer: A Systematic Review and Meta\u2010Analysis","volume":"9","author":"Xiao B. Y.","year":"2020","journal-title":"Translational Cancer Research"},{"issue":"3","key":"e_1_2_13_74_1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and Atezolizumab in Triple\u2010Negative Breast Cancer","volume":"70","author":"Kwapisz D.","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"5","key":"e_1_2_13_75_1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic Complete Response (pCR) to Neoadjuvant Treatment With or Without Atezolizumab in Triple\u2010Negative, Early High\u2010Risk and Locally Advanced Breast Cancer: NeoTRIP Michelangelo Randomized Study","volume":"33","author":"Gianni L.","year":"2022","journal-title":"Annals of Oncology"},{"issue":"1","key":"e_1_2_13_76_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-13105-9","article-title":"PD\u20101\/PD\u2010L1 Immune Checkpoint Inhibitors in the Treatment of Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer: A Meta\u2010Analysis on Their Efficacy and Safety","volume":"24","author":"Wang Z.","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"e_1_2_13_77_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/14737140.2022.2023011","article-title":"Atezolizumab and Pembrolizumab in Triple\u2010Negative Breast Cancer: A Meta\u2010Analysis","volume":"22","author":"Latif F.","year":"2022","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"22","key":"e_1_2_13_78_1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab\u2010Paclitaxel in Advanced Triple\u2010Negative Breast Cancer","volume":"379","author":"Schmid P.","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"e_1_2_13_79_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab Plus Chemotherapy in Advanced Triple\u2010Negative Breast Cancer","volume":"387","author":"Cortes J.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"e_1_2_13_80_1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple\u2010Negative Breast Cancer","volume":"382","author":"Schmid P.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"e_1_2_13_81_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating Extracellular Matrix Stiffness: A Strategic Approach to Boost Cancer Immunotherapy","volume":"15","author":"Mai Z.","year":"2024","journal-title":"Cell Death & Disease"},{"issue":"1","key":"e_1_2_13_82_1","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01717-y","article-title":"Extracellular Matrix Dynamics in Tumor Immunoregulation: From Tumor Microenvironment to Immunotherapy","volume":"18","author":"Hu Q.","year":"2025","journal-title":"Journal of Hematology & Oncology"},{"issue":"7","key":"e_1_2_13_83_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076170","article-title":"The Interplay Between Integrins and Immune Cells as a Regulator in Cancer Immunology","volume":"24","author":"Zhang Q.","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"e_1_2_13_84_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14728222.2014.980235","article-title":"The PD\u20101\/PD\u2010L1 Pathway: Biological Background and Clinical Relevance of an Emerging Treatment Target in Immunotherapy","volume":"19","author":"Muenst S.","year":"2015","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"9","key":"e_1_2_13_85_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/21645515.2016.1175694","article-title":"Nivolumab, Anti\u2010Programmed Death\u20101 (PD\u20101) Monoclonal Antibody Immunotherapy: Role in Advanced Cancers","volume":"12","author":"Rajan A.","year":"2016","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"10","key":"e_1_2_13_86_1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The Multifaceted Roles of PARP1 in DNA Repair and Chromatin Remodelling","volume":"18","author":"Ray Chaudhuri A.","year":"2017","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"1","key":"e_1_2_13_87_1","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-025-00385-1","article-title":"PARPs and PARP Inhibitors: Molecular Mechanisms and Clinical Applications","volume":"6","author":"Wang F.","year":"2025","journal-title":"Molecular Biomedicine"},{"issue":"1","key":"e_1_2_13_88_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13072-024-00550-w","article-title":"Transcriptional Regulation Mechanism of PARP1 and Its Application in Disease Treatment","volume":"17","author":"Lu Y.","year":"2024","journal-title":"Epigenetics & Chromatin"},{"key":"e_1_2_13_89_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose M.","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"6","key":"e_1_2_13_90_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation","volume":"377","author":"Robson M.","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"e_1_2_13_91_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer","volume":"32","author":"Eikesdal H. P.","year":"2021","journal-title":"Annals of Oncology"},{"key":"e_1_2_13_92_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","article-title":"Olaparib: First Global Approval","volume":"75","author":"Deeks E. D.","year":"2015","journal-title":"Drugs"},{"issue":"11","key":"e_1_2_13_93_1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/onc.2015.212","article-title":"Targeting of \u03b21 Integrins Impairs DNA Repair for Radiosensitization of Head and Neck Cancer Cells","volume":"35","author":"Dickreuter E.","year":"2016","journal-title":"Oncogene"},{"issue":"20","key":"e_1_2_13_94_1","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1158\/1078-0432.CCR-21-0310","article-title":"Niraparib for Advanced Breast Cancer With Germline BRCA1 and BRCA2 Mutations: The EORTC 1307\u2010BCG\/BIG5\u201013\/TESARO PR\u201030\u201050\u201010\u2010C BRAVO Study","volume":"27","author":"Turner N. C.","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"e_1_2_13_95_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9090110","article-title":"Integrins as Therapeutic Targets: Successes and Cancers","volume":"9","author":"Raab\u2010Westphal S.","year":"2017","journal-title":"Cancers"},{"issue":"7","key":"e_1_2_13_96_1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.7150\/ijms.34365","article-title":"Anti\u2010Tumor Activity and Pharmacokinetics of AP25\u2010Fc Fusion Protein","volume":"16","author":"Pei D.","year":"2019","journal-title":"International Journal of Medical Sciences"},{"issue":"9","key":"e_1_2_13_97_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/protein\/gzx022","article-title":"Half\u2010Life Extension Using Serum Albumin\u2010Binding DARPin Domains","volume":"30","author":"Steiner D.","year":"2017","journal-title":"Protein Engineering, Design & Selection"},{"issue":"4","key":"e_1_2_13_98_1","doi-asserted-by":"crossref","first-page":"C762","DOI":"10.1152\/ajpcell.00022.2022","article-title":"Epigenetic Regulation and Targeting of ECM for Cancer Therapy","volume":"322","author":"Gupta R.","year":"2022","journal-title":"American Journal of Physiology\u2010Cell Physiology"},{"issue":"6","key":"e_1_2_13_99_1","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/jbm.a.36360","article-title":"Biomimetic Peptide Display From a Polymeric Nanoparticle Surface for Targeting and Antitumor Activity to Human Triple\u2010Negative Breast Cancer Cells","volume":"106","author":"Bressler E. M.","year":"2018","journal-title":"Journal of Biomedical Materials Research\u2010Part A"},{"issue":"1","key":"e_1_2_13_100_1","first-page":"1","article-title":"Comprehensive Comparison of Theranostic Nanoparticles in Breast Cancer","volume":"11","author":"Nikdouz A.","year":"2022","journal-title":"American Journal of Clinical and Experimental Immunology"},{"key":"e_1_2_13_101_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171075","article-title":"Gel\u2010Forming Therapeutic Peptide Exhibits Sustained Delivery and Efficacy in a Mouse Model of Triple\u2010Negative Breast Cancer","volume":"169","author":"Patil A.","year":"2023","journal-title":"Peptides"},{"issue":"7","key":"e_1_2_13_102_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as Therapeutics","volume":"9","author":"Keefe A. D.","year":"2010","journal-title":"Nature Reviews Drug Discovery"},{"key":"e_1_2_13_103_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/B978-0-323-85881-6.00009-9","volume-title":"Aptamers Engineered Nanocarriers for Cancer Therapy","author":"Banazadeh M.","year":"2023"},{"key":"e_1_2_13_104_1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.omtn.2023.08.015","article-title":"Targeting Triple\u2010Negative Breast Cancer Cells With a \u03b21\u2010Integrin Binding Aptamer","volume":"33","author":"Pleiko K.","year":"2023","journal-title":"Molecular Therapy\u2014Nucleic Acids"},{"issue":"3","key":"e_1_2_13_105_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as Targeted Therapeutics: Current Potential and Challenges","volume":"16","author":"Zhou J.","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"key":"e_1_2_13_106_1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.talanta.2019.03.016","article-title":"An ssDNA Aptamer Selected by Cell\u2010SELEX for the Targeted Imaging of Poorly Differentiated Gastric Cancer Tissue","volume":"199","author":"Li W.","year":"2019","journal-title":"Talanta"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:03:42Z","timestamp":1791867822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/cam4.72247"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72247","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2025-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72247"}}